Bayer/Sontra
This article was originally published in The Gray Sheet
Executive Summary
Continuous, non-invasive glucose monitoring technology development by Sontra gets a boost from $1.5 mil. exclusive, worldwide license pact with glucose monitor company Bayer. The firms anticipate future collaboration agreements for development and commercialization of a monitor incorporating Sontra's SonoPrep ultrasonic skin permeation and biosensor technologies. Baxter will make the initial payment by Jan. 15, 2004, contingent on several factors, including Sontra achieving $2.5 mil. in stockholder equity by Sept. 30 and raising $1.5 mil. from other parties...
You may also be interested in...
Glucose, Needle-Free Vaccines Hold Promise For Sontra Ultrasound Device
Sontra Medical expects to complete three early-phase clinical studies on its Symphony Diabetes Management System for continuous glucose monitoring in 2005 as part of an exclusive licensing agreement with Bayer Diagnostics
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.